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Variable Hazard Ratio (95% CI) p value
PD-L2 (High vs. Low) 1.746 (0.592, 5.150) 0.3128
AGE 1.045 (1.003, 1.089) 0.0369
GENDER (Female vs. Male) 0.756 (0.287, 1.990) 0.5714
IDH1 MUTATION (Yes vs. No) 0.233 (0.083, 0.652) 0.0056
LGG N=528, p<0.0001
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Supplementary Figure Legends 
 
 
Supplementary Figure 1.  PD-L2 expression across cancer types.  (A) PD-L2 mRNA expression by Z-
score in the subset of lung tumor cell lines (top), skin tumor cell lines (middle) and kidney tumor cell lines 
(bottom) from the CCLE. (B) PD-L2 mRNA expression by Z-score in TCGA GBM and LGG datasets.  (C)  
PD-L2 expression by mRNA Z-score in TCGA lung adenocarcinoma patients (top), TCGA skin cutaneous 
melanoma patients (middle) and TCGA kidney renal clear cell carcinoma patients (bottom). 
 
Supplementary Figure 2. IFN-g induces the expression of PD-L1 in brain tumors.  (A) IFN-g stimulation 
of meningioma (IOMM-Lee and CH-157) and GBM (DBMTRMG, KNS60, LN340, and LN464) cell lines 
induces the cell surface expression of PD-L1 assessed by flow cytometry.  (B) IFN-g stimulation of BTIC 
lines (B86, B18, and B49) induces the cell surface expression of PD-L1 assessed by flow cytometry. 
 
Supplementary Figure 3.  Perturbation of GATA2 and GATA3 levels in brain tumors.  Overexpression 
levels of GATA2 mRNA in (A) LN464 cells and (B) LN340 cells measured by qRT-PCR. (C)  
Overexpression of GATA3 mRNA in LN340 cells by qRT-PCR.  (D) Overexpression of GATA3 in LN340 
is not sufficient to induce PD-L2 protein expression by flow cytometry (grey line: antibody staining 
in control cells; black line: antibody staining in GATA3-transduced cells). (E) PD-L2 mRNA 
expression in IOMM (left) or AM38 (right) cells transduced with control shRNA or shRNA constructs 
targeting PD-L2. 
 	
Supplementary Figure 4.  Multivariate analysis of OS in LGG.  (A)  Correlation between PD-L2 and PD-
L1 expression values in LGG patients (Pearson Correlation Coefficients, N=528, r=0.57466, p<0.0001) 
(left) and GBM patients (Pearson Correlation Coefficients, N=165, r=0.51527, p<0.0001) (right). (B) 
Multivariate analysis for OS shows PD-L2 is not an independent factor in LGG patients after adjusted by 
covariates including age, gender and IDH1 mutation (p=0.3128). 
 
Supplementary Figure 5.  Knockdown of GATA2 protein levels in brain tumors.  Knockdown levels of 
GATA2 protein in (A) IOMM cells and (B) AM38 cells measured by Western Blot. (A) Actin and GATA2 blot 
images were cropped from the same gel. Left panel is the actin full image and right panel is GATA2 full blot 
image in IOMM cell lines transduced with control shRNA or shRNA constructs targeting PD-L2.  (B) Actin 
and GATA2 blot images were cropped from the same gel. Left panel is the GATA-2 full image and right 
panel is actin full blot image in AM38 cell lines control shRNA or shRNA constructs targeting PD-L2. Top 
panel and bottom panel are in different exposure time. 
 
 
 
 
